newsfilter
← Latest News
GlobeNewswire·

NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results

--Announced that the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration did not meet primary endpoint of statistically significant rate of change in GA